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Abstract
Background: An Individual Patient Data (IPD) meta-analysis is often considered the gold-standard for synthesising
survival data from clinical trials. An IPD meta-analysis can be achieved by either a two-stage or a one-stage
approach, depending on whether the trials are analysed separately or simultaneously. A range of one-stage
hierarchical Cox models have been previously proposed, but these are known to be computationally intensive and
are not currently available in all standard statistical software. We describe an alternative approach using Poisson
based Generalised Linear Models (GLMs).
Methods: We illustrate, through application and simulation, the Poisson approach both classically and in a
Bayesian framework, in two-stage and one-stage approaches. We outline the benefits of our one-stage approach
through extension to modelling treatment-covariate interactions and non-proportional hazards. Ten trials of
hypertension treatment, with all-cause death the outcome of interest, are used to apply and assess the approach.
Results: We show that the Poisson approach obtains almost identical estimates to the Cox model, is additionally
computationally efficient and directly estimates the baseline hazard. Some downward bias is observed in classical
estimates of the heterogeneity in the treatment effect, with improved performance from the Bayesian approach.
Conclusion: Our approach provides a highly flexible and computationally efficient framework, available in all
standard statistical software, to the investigation of not only heterogeneity, but the presence of non-proportional
hazards and treatment effect modifiers.
Background
Meta-analysis methods are used to integrate quantitative
findings from a set of related research studies with the
aim of providing more reliable and accurate estimates of
a treatment effect [1]. Traditionally a meta-analysis
requires aggregate data (AD), extracted from publications
or received directly from study authors. Summary statis-
tics (e.g. log hazard ratios) are then synthesised using a
fixed or random effects meta-analysis [2], where random
effects can account for between study heterogeneity in
the treatment effect. Meta-regression models [3] attempt
to explain this excess heterogeneity with study-level
covariates. However, the use of AD to conduct a meta-
analysis has inherent problems, for example, hazard
ratios are not always explicitly given in publications,
leading to the development of alternative techniques to
extract appropriate summary statistics [4]. Despite this,
even when using the methods of Parmar et al., it can still
be difficult to extract hazard ratios, as shown by Riley
et al. [5].
An approach often considered the gold-standard alter-
native to an AD meta-analysis is a meta-analysis of indi-
vidual patient data (IPD), which utilises the raw data
from each study. IPD meta-analyses have been shown to
be most common when analyzing time-to-event data [6].
The benefits of conducting an IPD meta-analysis with
time-to-event data include: follow-up time can be longer
and more up to date, analyses can be standardised across
studies, model assumptions can be checked e.g. propor-
tional hazards, and confounders can be adjusted for.
However, IPD can be difficult to obtain, and a variety of
methods have been developed to undertake meta-ana-
lyses from the published literature of time-to-event data.
An early proposal by Dear [7] showed how to jointly
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synthesise survival proportions reported at multiple
times, by utilising their correlation and combining them
in a multivariate meta-analysis using generalised least
squares. Dear investigated only fixed effects, leading the
extension of Arends et al. to incorporate random effects
[8]. Techniques to extract summary statistics from pub-
lished studies have also been demonstated [4] for the use
in standard AD meta-analyses. Fiocco et al. recently used
a Poisson correlated gamma-frailty approach to combine
survival curves under heterogeniety, allowing the investi-
gation of both between-study variance and within and
between-arm correlations [9]. A frailty approach has also
been implemented by Feng et al. incorporating crossed
random effects using penalized quasi-likelihood under a
Poisson likelihood [10]. Further extensions of AD meta-
analyses include assessment of the proportional hazards
assumption [9,11]
IPD meta-analyses of time-to-event data can use either a
two-stage or one-stage approach. The most commonly
used, the two-stage, is achieved by first fitting individual
survival models to each trial. The chosen estimates of
effect are then combined in a standard meta-analysis fra-
mework, now equivalent to an AD meta-analysis. In a
one-stage IPD meta-analysis, patient data from all studies
are analysed simultaneously within a hierarchical frame-
work. This draws parallels with the analysis of IPD from
multi-centre clinical trials, accommodating clustering
within treatment centres; however, in a multi-centre trial
the treatment effect is not often random, whereas in a
meta-analysis it often is. This is because in a multi-centre
trial we can achieve greater consistency in inclusion/exclu-
sion criteria and other aspects of trial protocol, indicating
that a fixed treatment effect is likely to be more appropri-
ate. Senn discusses these issues in more detail [12], but we
emphasise that, although random-effects models are rarely
used to analyse multi-centre trials, they could also adopt
the methods we present here. Indeed, published trial ana-
lysis guidelines do state: “mixed models may be used to
explore heterogeneity of the treatment effect. These mod-
els consider centre and treatment-by-centre effects to be
random, and are especially relevant when the number of
sites is large” [13]. A range of hierarchical survival models
within the Cox framework have been developed [14-17],
which can effectively account for heterogeneity in treat-
ment effect and baseline risk. However, these methods can
have a high computational burden and/or rely on user-
written programs, not currently available in standard sta-
tistical software [16]. Furthermore, these models do not
investigate the validity of the assumption of proportional
hazards. These reasons serve as motivation to consider
alternative approaches, such as the percentile ratio [18] as
a target of inference in this setting, developed predomi-
nantly for when the proportional hazards assumption
appears violated.
The aim of this paper is to explore the use of Poisson
regression, and the generalised mixed model extensions,
to incorporate random effects to perform one- and two-
stage IPD meta-analyses of time-to-event outcomes, as
an alternative to hierarchical Cox models, and to extend
the models to incorporate non-proportional hazards and
treatment-effect modifiers.
Methods
The Poisson approach to survival analysis
Poisson regression is used in the modelling of count data
and contingency tables; however, the extension to model-
ling survival data via a piecewise exponential model [19]
serves as an alternative approach to the widely used Cox
model. It has been shown how the Cox model can be
fitted using a Poisson GLM due to the shared form of the
contribution to the partial log-likelihood, by splitting fol-
low-up time into as many intervals as there are events
[20]. However, this method can be computationally
intensive. Alternatively, we can choose a smaller number
of time intervals with fixed length, where patients are at
risk of experiencing events within these [21], to closely
approximate the Cox model. We also obtain direct esti-
mates of the baseline hazard rate. Fine splitting of the
timescale has been used to allow the use of splines and
fractional polynomials to model the baseline hazard con-
tinuously [21,22].
A standard approach when choosing interval lengths is
to use yearly splits [23]. The narrower the time interval,
the more computationally intensive these methods will
be; however, methods to compensate for this are available
and described below. The shape of the underlying hazard
function plays a crucial role in choosing the number of
intervals necessary to successfully capture its variation. In
this paper, quarter year, half year and yearly splits are
compared.
Undertaking a one-stage IPD meta-analysis within a
Poisson framework is beneficial due to the highly devel-
oped area of GLMs. Random effects GLMs are available
within all commonly used statistical software packages
(e.g. Stata, SAS and R), allowing models to be applied
without the need for specialist software.
Model fitting in a single trial
Consider the analysis of time-to-event data from a single
trial, investigating the effect of a treatment. For the ith
patient, let xi denote treatment group, coded 0/1 to
denote control/treatment. A standard Cox proportional
hazards model can be applied (and estimated by maxi-
mising the partial likelihood [24]):
hi(t) = h0(t)exp(β1xi) (1)
where h0(t) is the unspecified baseline hazard rate and
b1 the log hazard ratio (i.e. the treatment effect) for the
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treatment group compared to the control group. By
splitting follow-up time into k = 1,...,K intervals and
assuming a constant hazard within each interval we can
apply the Poisson model:
dik ∼ Poisson(μik)
log(μik) = β1xi + λk + log(yik)
(2)
where dik is the event indicator, taking the value of 0
or 1 (censored or event), representing a Poisson process
for each patient during each time interval. Note that dik
will not follow a Poisson distribution per se, but by
doing so we recover the correct form of the likelihood
for a piecewise exponential model. b1 is once again the
log hazard ratio for the treatment group compared to
the control group. lk is the baseline hazard rate during
the kth time interval. Time at risk, yik, is included as a
log offset in the linear predictor. If we split follow-up
time at each unique event time and apply the Poisson
model, we would obtain an identical estimate of the
treatment effect, b1, to that from a Cox model.
Two-stage IPD meta-analyses models for survival data
The two-stage approach can be thought of as more tra-
ditional, with individual survival models applied to each
trial, and appropriate summary statistics extracted to
allow AD meta-analysis techniques to be applied.
We extract from the jth trial: the log hazard ratio for
the treatment group compared to the control group,
βˆ1j , and its variance V(βˆ1j) , using either Cox or Pois-
son models, which can then be combined in a standard
AD meta-analysis. Such AD meta-analysis models
include a fixed effect model, where we assume all trials
are estimating the same true treatment effect, applied
for example using the inverse variance weighted method
[1]. Alternatively, a random effect model can be applied
where we assume that each estimate of the treatment
effect comes from a distribution of treatment effects,
with mean b1 and variance τ
2. Following a random effect
meta-analysis, a prediction interval can be calculated for
the predicted treatment effect in an individual study, to
help show the potential impact of between-trial hetero-
geneity [25,26].
One-stage IPD meta-analyses models for survival data
We now describe one-stage IPD meta-analyses models
using the framework of proportional hazards models.
The following models, if fitted using the Cox propor-
tional hazards model, correspond to those developed by
Tudur-Smith et. al. [14], which are estimated by maxi-
mising the penalized partial likelihood to find the best
linear unbiased predictors, from which the REML esti-
mators of the variance components were found [27].
Model A: Fixed treatment effect with proportional trial
effects
For the ith patient, i = 1,...,nj, in the j
th trial, j = 1,...,J, the






where h0(t) is the baseline hazard function in the
reference trial (say j = 1, so b01 constrained to be zero).
b0j is the proportional effect on the baseline hazard
function due to the jth trial, now j = 2,..., J. xij is coded
-0.5/0.5 to denote control/treatment group and b1 is the
log hazard ratio for the treatment group compared to
the control group, assumed equal across all trials. Model
A makes the restrictive assumption that the hazard
functions in all trials are proportional to a common
baseline function.
The treatment group coding of -0.5/0.5 is used in all
one-stage models presented in this paper. Using this
coding of the treatment group indicator, we assume
equal variability in the log hazard rate across trials for
both treatment groups. If we chose the 0/1 coding, this
imposes the restrictive assumption that the variability in
the log hazard rate of the treatment group coded 0, is
zero [14,28].
Model B: Fixed treatment effect with baseline hazard
stratified by trial
In reality, the assumption that the hazard functions in
all trials are proportional is likely to be inappropriate.
By allowing separate baseline hazard functions for each
trial we can relax this assumption, whilst still assuming
proportional hazards between treatment groups within
each trial. Allowing separate baseline hazards, we have:
hij(t) = h0j(t)exp(β1x1ij) (4)
where h0j(t) is the baseline hazard function in the j
th
trial. As in Model A, b1 represents the log hazard ratio
for the treatment group compared to the control group,
assumed constant across trials. No allowance for
between study variation in the treatment effect is made
in Models A and B.
Model C: Random treatment effect with proportional trial
effects
Models which allow for between-trial heterogeneity in
the treatment effect are now considered. The following
formulations assume an underlying mean treatment
effect, coming from a population of treatment effects.
The hazard function for the ith patient in the jth trial





β1j = β1 + b1j
b1j ∼ N(0, τ 2)
(5)
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where h0(t) is the baseline hazard function in the
reference trial (say j = 1, so b01 constrained to be zero).
b0j is the proportional effect on the baseline hazard
function due to the jth trial, now j = 2,...,J. b1 is now
interpreted as the mean log hazard ratio for a popula-
tion of treatment effects, with b1j the deviation of the
log hazard ratio in the jth trial from the population
mean. This assumes that the b1j’s come from a Normal
distribution with mean zero and variance τ2. This for-
mulation produces a measure of the between-trial het-
erogeneity in the treatment effect, τ2.
Model D: Random treatment effect with baseline hazard
stratified by trial






β1j = β1 + b1j
b1j ∼ N(0, τ 2)
(6)
where h0j(t) is interpreted as in Model B, with b1, bij
and τ2 defined in Model C. Model D, as in Model B,
assumes proportional hazards across treatment groups
only within trials.
Models A to D, within a hierarchical Cox framework,
were applied by Tudur-Smith et al. [14] to IPD data
from 5 trials comparing 2 anti-epileptic drugs with
time-to-event outcome first seizure. A total of 1225
patients were analysed. To illustrate the computational
burden of hierarchical Cox models, the application of
Model C took 29 hours to achieve convergence, whilst
the application of Model D took 53 minutes to achieve
convergence.
The Poisson approach to one-stage IPD meta-analysis
models of survival data
We now introduce Poisson based GLM formulations of
the models shown above. Techniques to increase the
computational efficiency of the models are described in
Section titled “Model fitting” below.
One-stage IPD Poisson generalised linear survival models
Models A and C: Fixed/random treatment effect with
proportional trial effects. For time intervals, k = 1,...,K,
we now have:
h0k(t) = λk (7)
where lk represents the constant hazard rate in the k
th
interval for the control group, in the reference trial.
Models B and D: Fixed/random treatment effect with
baseline hazard stratified by trial. Models B and D are
similarly altered. For trials, j = 1,...,J, and time intervals,
k = 1,...,K, we can write the baseline hazard function as:
h0jk(t) = λjk (8)
where ljk represents the constant hazard rate in the j
th
trial during the kth time interval.
Model fitting
We present Model A in the form of a Poisson GLM:
dijk ∼ Poisson(μijk)
log(μijk) = β0j + β1xij + λk + log(yijk)
(9)
where dijk is the event indicator, taking the value of 0
or 1 (censored or event), representing a Poisson process
for each patient in each trial during each time interval.
b0j and b1 are as in Model A, with lk once again the
hazard rate in the control group of the reference trial.
Time at risk, yijk, is included as a log offset in the linear
predictor. The extension to separate trial effects can be
achieved by simply replacing the linear b0j and lk terms
with the interaction of them, i.e. Model B.
Fixed effect Models A and B can be implemented
using any GLM software package, such as glm within
Stata [29]. Models C and D, with random treatment
effects, can be implemented using a multilevel mixed
effects Poisson regression package, such as Stata’s
xtmepoisson.
It is widely known that within a mixed effects frame-
work, maximum likelihood performs poorly when esti-
mating variance parameters when there are a small
number of studies [28]. This provides motivation for
considering a Bayesian approach to the models dis-
cussed above, described and undertaken in the simula-
tion study and results sections below.
If we have N independent Poisson distributed random
variables, each with mean l, then the sum of these N
distributions is itself a Poisson distributed random vari-
able with mean Nl. Given this condition, it is possible
to ‘collapse’ each split dataset across covariate patterns
(for example, separately collapse the dataset for males
and females) [30]. A Poisson GLM model can then be
fitted to the collapsed dataset, giving identical parameter
estimates to a Poisson GLM fitted to the non-collapsed
dataset. This process dramatically reduces computation
time when datasets are large; however, is only valid
when categorical covariates are used. It is not possible
to collapse across covariate patterns when including
truly continuous covariates.
When handling sparse event data, the situation may
arise when no events occur within a split time interval.
In this case, when applying the models described in this
section, we obtain nuisance estimates of the baseline
hazard rate for any time interval in which no events
occur. This can be remedied by the merging of time
intervals.
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Simulation study
To fully assess the performance of these methods a
simulation study was devised. Data is simulated consist-
ing of a random treatment effect and proportional trial
effects. We investigate the impact of the number of stu-
dies and time interval length by simulating either 5, 10
or 30 trials, and applying Poisson one-stage models with
time intervals of length 0.25, 0.5 or 1 year. Each trial is
simulated under the following steps:
1. Generate 2000 patients; 50% assigned to treat-
ment, 50% to control.
2. Simulate a random treatment effect (on the log
scale) with mean, a = -0.4, and inherent between-
trial heterogeneity, τ = 0.2. Therefore b1 ~ N
(-0.4,0.22), indicating a 33.0% (95% CI: 0.8%, 54.7%)
reduction in the event rate due to treatment.
3. Generate a fixed trial effect, b0 ~ N(0,0.52), again
on the log scale.
4. Generate survival times from a Weibull distribu-
tion using a formulation proposed by Bender et al.
[31]. Scale and shape parameters were defined as l =
0.042 and g = 1.2, respectively. These values are based
on fitting a Weibull survival model to the SHEP trial.
All observations are censored after 5 years. This pro-
duces a 74.8% and 82.4% survival proportion after
5 years in the control and treatment groups,
respectively.
This results in 9 scenarios, in which 1000 repetitions
were simulated. For each simulated dataset, Model C
was applied both classically using xtmepoisson within
Stata, whilst WinBUGS, through the use of winbugs-
fromstata[32], was used to apply the equivalent Baye-
sian model. Each Bayesian model was applied with a
burn-in of 1000 and sample of 5000. This was deemed
adequate to achieve convergence through extensive test-
ing of the simulations. Vague priors were assigned to all
parameters under the Bayesian approach. The treatment
group indicator was coded -0.5/0.5.
Extensions to the one-stage approach
Treatment effect modifiers
It is becoming increasingly accepted that variation in
treatment effects, as a source of heterogeneity, can only
be sufficiently detected and explained when IPD are
available [33]. IPD allows one to examine covariates and
within-trial interactions at the patient-level. In contrast,
meta-regression of only AD allows one to examine study-
level covariates and interactions across-trials, and this
has been shown to have low power to detect true interac-
tions between patient covariates and treatment effect
[34], and may also be subject to ecological bias and study
level confounding [35].
The discrimination between within-trial and across-
trial treatment-covariate interactions is a current issue
in IPD meta-analysis [35,36], which requires further
work within the survival analysis field. Below we present
a simple one-stage model which produces a weighted
average of the within- and across-trial interactions,
though in our applied example the within-trial interac-
tion dominates.
Fixed treatment effect with separate trial effects Let
wij be a patient-level covariate, e.g. overweight status
(coded 0/1 for no/yes, see Table 1) for the ith patient in
the jth trial. Extending Model B to incorporate a treat-
ment-covariate interaction gives:
hijk(t) = λjkexp(β1xij + μwij + γ xijwij) (10)
where ljk is the baseline hazard rate during the kth
time interval in the jth trial, b1 now represents the treat-
ment effect when wij = 0, μ is the change in the log
hazard rate of the control group for a one-unit increase
in wij and g is the change in the treatment effect for a
one-unit increase in wij.
Table 1 Summary statistics for the IPD meta-analysis investigating effectiveness of anti-hypertension drugs
Trial Total number of patients All-Cause Deaths Percent Overweight (%)
Control Treatment Control Treatment Control Treatment
ATMH 754 785 13 9 64.24 65.69
COOP 199 150 22 20 51.25 56.00
EWPH 82 90 25 24 62.20 63.33
HDFP 2371 2427 82 81 74.02 71.86
MRC1 3445 3546 63 67 67.52 69.57
MRC2 1337 1314 156 138 61.11 60.81
SHEP 2371 2365 229 210 67.95 68.84
STOP 131 137 7 4 58.78 63.50
SYCH 1121 1239 77 56 39.77 38.66
SYSE 2285 2380 126 115 68.39 68.31
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Non-proportional hazards for the treatment effect
It has been shown that the benefits of a treatment can be
deemed greater during the initial period of follow-up time
in certain contexts [37]. In this situation, an assumption of
proportional hazards for the treatment effect will be vio-
lated. In other words, a beneficial treatment effect may
diminish with time. We describe a simple approach of
investigating the presence of non-proportional hazards in
the treatment effect, which can be extended to any covari-
ate within the model.
Fixed treatment effect with separate trial effects
Extending Model B, we first dichotomise follow-up time
at time ts, and define a variable, zijk, which takes the






βˆ1 now represents the log hazard ratio for the treat-
ment group compared to the control group when t <ts,
with φˆ the change in the log hazard ratio when t ≥ ts,
relative to when t <ts. The estimated log hazard ratio for
the treatment group compared to the control group
when t ≥ ts is therefore a linear combination; βˆ1 +φˆ .
The inclusion of non-proportional hazards can be inves-
tigated using the likelihood ratio test, comparing with
Model B.
This can be extended by further splitting of follow-up
time; however, the time variable, zijk, would generally be
assumed to have fewer intervals than those used to
model the baseline hazard rate. Extension to include a
time-varying treatment effect in Models A, C and D is
easily conducted.
The hypertension data
The example dataset used to illustrate the models in this
paper comes from an IPD meta-analysis investigating
the effects of anti-hypertension drugs in lowering systo-
lic and diastolic blood pressure as determinants of cardi-
ovascular outcomes [38]. Randomised controlled trials
(RCTs) were selected on the availability of IPD and the
comparison of an active treatment to a placebo or con-
trol. This resulted in the inclusion of 10 trials consisting
of 28,581 patients. Meta-analysis is important to sum-
marise the average treatment effect, and any heterogene-
ity in the treatment effect, across these different trials,
and it enables a broader assessment of the effects of
hypertension treatments than is possible in a single trial
alone.
Summary statistics for the time-to-event outcome all-
cause death and an overweight covariate are presented
in Table 1. Overweight status is a binary covariate,
coded 0/1 for no/yes, dichotomising Body-Mass Index
(BMI) at 25 kg/m2. Detailed summary statistics can be
found in the original meta-analysis [38].
Results
Single trial application
Comparing approaches, we apply a proportional hazards
model investigating the effect of the treatment. The
SHEP trial is used as an example, with outcome all-
cause death. Estimated hazard ratios for the treatment
effect are presented in Table 2. We observe complete
agreement in estimates and 95% confidence intervals
across models, showing a non-statistically significant
reduction of 8.7% (95% CI: -10.1%, 24.3%) in the hazard
of death for patients in the anti-hypertension treatment
group compared to those in the control group.
Two-stage IPD meta-analyses models for survival data
We now apply two-stage random effects meta-analyses
models to the hypertension data. In the first step we
compare the Cox and Poisson models to obtain the esti-
mates of the treatment effect in each trial, βˆ1j and asso-
ciated variance V(βˆ1j) . The second step is then
conducted using the random effects AD meta-analysis
model of DerSimonian and Laird [2].
Table 3 shows the estimates of the pooled hazard
ratio. All 4 models produce consistent estimates of the
pooled treatment effect, showing a 12% (95% CI: 2.6%,
20.4%) reduction in the hazard of death for patients in
the active anti-hypertension treatment group compared
to those in the control. No evidence of heterogeneity
was found (τˆ 2 = 0) , indicating in this case a fixed effect
model would suffice and would yield identical estimates.
Forest plots from the two-stage meta-analyses using Cox
models and Poisson models with 0.5 year splits are
shown in Figures 1 and 2, respectively, illustrating the
consistent estimates of the treatment effect at both the
trial and meta-analysis level.
One-stage IPD meta-analyses models for survival data
We now apply each of the models described in the
methods section “One-stage IPD meta-analyses models
for survival data” to the hypertension data, using the
Poisson method both classically and under a Bayesian
approach. Further comparison of Models A(fixed treat-
ment and fixed proportional trial effects) and B (fixed
treatment and baseline stratified by trial) are made using
Cox proportional hazards models, under a classical
approach. Under Bayesian Models A, B, C and D all
Table 2 Estimates of treatment effect in the SHEP trial
Method Hazard ratio 95% CI
Cox 0.913 0.757 1.101
Poisson (1) 0.913 0.757 1.101
Poisson (0.5) 0.913 0.757 1.101
Poisson (0.25) 0.913 0.757 1.101
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parameters are assigned a vague prior of N(0,10002),
excluding the heterogeneity parameter in Models C and
D, where τ ~ N(0,1) with τ > 0. A burn-in of 1000 was
used, with 100,000 samples and thinning at every 20th
sample to remove autocorrelation.
Estimates of the treatment effect and 95% confidence/
credible interval are seen in Table 4. Comparing esti-
mates obtained under classical Cox formulations of
Models A and B with equivalent Poisson models, we
observe almost identical estimates of the treatment
effect and 95% confidence intervals for each time inter-
val length. For example, under all 4 classical one-stage
IPD meta-analysis models with fixed treatment effect
and proportional trial effects, we observe a 12.3% (95%
CI: 3.0%, 20.7%) reduction in the hazard of death for
patients in the active anti-hypertension treatment group
compared to those in the control group. Consistent esti-
mates of the treatment effect are obtained across all 3
choices of time interval.
Each mixed effects model also produces an estimate of
heterogeneity in the treatment effect, seen in Table 5.
Stark contrasts in estimates of τ can be seen between
classical and Bayesian approaches to both Models C and
D. For example, under a classical one-stage Poisson
model (with time intervals of 1 year) with random treat-
ment effect, stratified by trial, we obtain an estimate of
heterogeneity of τ = 5.92E-09 (95% CI: 0, .), compared
NOTE: Weights are from random effects analysis







































Favours treatment  Favours control 
1.1 .25 .5 2 4
Hazard ratios from Cox models
Random effects Meta−Analysis of Hazard Ratios
Figure 1 Two-stage meta-analyses with outcome all-cause death. Cox models are used in the first step.
Table 3 Results from two-stage random effects meta-
analyses.
Model Pooled Hazard Ratio 95% CI τˆ
2
Cox 0.880 0.796 0.974 0
Poisson (0.25) 0.881 0.796 0.974 0
Poisson (0.5) 0.880 0.796 0.974 0
Poisson (1) 0.880 0.796 0.973 0
Outcome is all-cause death
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NOTE: Weights are from random effects analysis







































Favours treatment  Favours control 
1.1 .25 .5 2 4
Poisson GLMs, interval length = 0.5 years
Random effects Meta−Analysis of Hazard Ratios
Figure 2 Two-stage meta-analyses with outcome all-cause death. Poisson GLMs are used in the first step.














Classical A Fixed Proportional 0.877 0.793 0.970 0.877 0.793 0.970 0.877 0.793 0.970 0.877 0.793 0.970
B Fixed Stratified 0.880 0.795 0.973 0.879 0.795 0.973 0.880 0.796 0.973 0.880 0.796 0.973
C Random Proportional - - - 0.877 0.793 0.970 0.877 0.793 0.970 0.877 0.793 0.970
D Random Stratified - - - 0.879 0.795 0.973 0.880 0.796 0.973 0.880 0.796 0.973
Bayesian A Fixed Proportional - - - 0.877 0.796 0.971 0.878 0.792 0.969 0.876 0.792 0.970
B Fixed Stratified - - - 0.880 0.796 0.971 0.879 0.793 0.975 0.879 0.794 0.971
C Random Proportional - - - 0.874 0.756 0.994 0.871 0.747 0.994 0.873 0.748 0.998
D Random Stratified - - - 0.876 0.755 0.996 0.876 0.755 1.002 0.873 0.760 1.000
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to the equivalent Bayesian models estimate of τ = 0.081
(95% Cred. Int.: 0.004, 0.310). The classical model has
estimated τ to be essentially zero, and consequently
failed to construct a 95% confidence interval.
To illustrate the computational efficiency of the
method, using interval lengths of 1 year; application of
Models C and D to collapsed data under a classical
approach took 4.6 seconds and 60 seconds, respectively,
to achieve convergence. Under a Bayesian approach the
equivalent models took 64 seconds and 63 seconds,
respectively, to complete the sampling.
Example code to fit Model C both classically within
Stata, and under a Bayesian approach in WinBUGS [39]
can be found in the Appendix.
Simulation results
Results from the simulation study, detailing mean esti-
mates and coverages of the treatment effect and hetero-
geneity can be found in Tables 6 and 7, respectively.
From Table 6, the treatment effect estimates appear con-
sistent across classical and Bayesian frameworks for each
model. A scatter plot matrix can be seen in Figure 3,
further illustrating agreement between classical and Baye-
sian estimates. Coverage improves as the number of trials
increase; however, within the classical models coverage is
much less informative due to the moderate downward
biases seen in the estimates of heterogeneity in Table 7.
There is clear evidence that, irrespective of the number
of trials or interval length, the classical mixed effects
models consistently underestimate the true underlying
heterogeneity of τ = 0.2. Estimates from the Bayesian
models are generally less biased. Figure 4 shows a scatter
plot matrix comparing classical and Bayesian estimates of
τ, illustrating the classical approach consistently produ-
cing lower estimates of τ, compared to the Bayesian
approach.
We also conducted the simulations described above
using a treatment group coding of 0/1. The estimates of
heterogeneity from the classical model had much larger
downward bias. For example, when using 0.5 year inter-
vals, estimates of τ for 5, 10 and 30 studies were 0.112,
0.138 and 0.165, respectively when using the 0/1 treat-
ment coding, compared with 0.147, 0.176 and 0.193
seen in Table 7 for the -0.5/0.5 coding. Estimates under
a Bayesian approach remained consistent with those
seen in Table 7.
We extended the simulation study to include applica-
tion of Model D (random treatment effect with baseline
hazard stratified by trial) to data simulated as described
above. Unfortunately, due to excessive computation time,
it proved infeasible to conduct the simulation study on
all 9 scenarios. For example, a single run of the scenario
including 10 trials with 0.25 year splits takes approxi-
mately 32 minutes. However, the 5 trial scenarios were
completed and showed entirely consistent results to
those described above. The computational difficulties are
Table 5 Estimates of heterogeneity from applying Models C and D both classically and under a Bayesian approach
Framework Model Treatment effect Trial effect Poisson (1) Poisson (0.5) Poisson (0.25)
τ 95% CI τ 95% CI τ 95% CI
Classical C Random Proportional 5.83E-10 0 . 2.01E-09 0 . 5.60E-09 0 .
D Random Stratified 5.92E-09 0 . 1.10E-11 0 . 4.90E-08 0 .
Bayesian C Random Proportional 0.082 0.004 0.310 0.085 0.004 0.319 0.081 0.004 0.321
D Random Stratified 0.081 0.004 0.310 0.080 0.004 0.299 0.077 0.003 0.306
Table 6 Results of simulation study.
Split time Model 5 Studies 10 Studies 30 Studies
0.25 Classical -0.402 -0.394 -0.396
84.9% 91.4% 92.7%
Bayesian -0.403 -0.396 -0.397
97.2% 96.2% 95.2%
0.5 Classical -0.401 -0.392 -0.396
84.8% 90.6% 92.7%
Bayesian -0.403 -0.393 -0.397
97.3% 96.0% 94.7%
1 Classical -0.401 -0.392 -0.396
84.8% 90.7% 92.7%
Bayesian -0.402 -0.393 -0.396
97.5% 95.6% 94.9%
Bayesian estimates are means of median values. Classical estimates are mean
values. True value, a = -0.4. Coverage in italics
Table 7 Results of simulation study.
Split time Model 5 Studies 10 Studies 30 Studies
0.25 Classical 0.147 0.177 0.193
- - 95.0%
Bayesian 0.230 0.213 0.205
95.2% 95.7% 94.3%
0.5 Classical 0.147 0.176 0.193
- - 95.0%
Bayesian 0.230 0.212 0.205
95.2% 94.4% 94.2%
1 Classical 0.147 0.176 0.193
- - 95.0%
Bayesian 0.231 0.212 0.207
95.1% 94.2% 93.9%
Bayesian estimates are means of median values. Classical estimates are mean
values. True value, τ = 0.2. Coverage in italics
Crowther et al. BMC Medical Research Methodology 2012, 12:34
http://www.biomedcentral.com/1471-2288/12/34





















−0.8 −0.7 −0.6 −0.5 −0.4 −0.3 −0.2 −0.1 0.0 0.1
Bayesian Estimate





















−0.8 −0.7 −0.6 −0.5 −0.4 −0.3 −0.2 −0.1 0.0 0.1
Bayesian Estimate





















−0.8 −0.7 −0.6 −0.5 −0.4 −0.3 −0.2 −0.1 0.0 0.1
Bayesian Estimate





















−0.8 −0.7 −0.6 −0.5 −0.4 −0.3 −0.2 −0.1 0.0 0.1
Bayesian Estimate





















−0.8 −0.7 −0.6 −0.5 −0.4 −0.3 −0.2 −0.1 0.0 0.1
Bayesian Estimate





















−0.8 −0.7 −0.6 −0.5 −0.4 −0.3 −0.2 −0.1 0.0 0.1
Bayesian Estimate





















−0.8 −0.7 −0.6 −0.5 −0.4 −0.3 −0.2 −0.1 0.0 0.1
Bayesian Estimate





















−0.8 −0.7 −0.6 −0.5 −0.4 −0.3 −0.2 −0.1 0.0 0.1
Bayesian Estimate





















−0.8 −0.7 −0.6 −0.5 −0.4 −0.3 −0.2 −0.1 0.0 0.1
Bayesian Estimate
(i) 1 year, 30 trials



















0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7
Bayesian Estimate



















0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7
Bayesian Estimate



















0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7
Bayesian Estimate



















0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7
Bayesian Estimate



















0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7
Bayesian Estimate



















0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7
Bayesian Estimate



















0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7
Bayesian Estimate



















0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7
Bayesian Estimate



















0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7
Bayesian Estimate
(i) 1 year, 30 trials
Figure 4 Scatter plot matrix comparing classical and Bayesian estimates of between-study standard deviation. True value, τ = 0.2.
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exclusively due to the classical approach, as each Baye-
sian model takes only seconds to execute the required
number of MCMC samples.
One-stage approach extensions
Treatment effect modifier
We apply Model (10), both classically and in a Bayesian
framework, to the hypertension data to examine whether
treatment effect is modified by being overweight (as
defined by a BMI value ≥ 25). Note we dichotomise BMI
to illustrate the methodology here, but in practice continu-
ous variables are better analysed on their continuous scale.
All parameters in the Bayesian approach use the vague
prior N(0,10002). Results are shown in Table 8. We
observe almost identical estimates across classical models
for each of the parameters of interest. When a patient is
not overweight, all classical models predict a treatment
effect reducing the mortality rate by approximately 14.2%
(95% CI: -0.1%, 26.4.4%, 21.6%) in the hazard of death for
overweight patients in the active anti-hypertension treat-
ment group compared to those in the control. Being over-
weight is estimated to produce a 27.4% (95% CI: 16.5%,
37.0%) reduction in the mortality rate, with treatment
group held constant. The equivalent Bayesian models pro-
duce almost identical estimates of effect compared to the
classical models. Using the approach of Riley et al. [36] we
also separated within-study and between-study interac-
tions but it did not change these findings.
Non-proportional hazards
We now apply Model (11) to the hypertension data, let-
ting ts = 1. Results are presented in Table 9. From the
classical models, a statistically significant (at the 5% level)
34.3% (95% CI: 16.2%, 48.5%) reduction in the hazard of
death for patients in the active anti-hypertension treat-
ment group compared to those in the control is observed
in the first year of follow-up. The treatment effect after
the first year is calculated by exp (b1 + j). This produces
a non-significant reduction of 6.4% (95% CI: -4.5%,
16.2%) in the hazard of death for patients in the active
anti-hypertension treatment group compared to those in
the control, showing evidence of a diminishing treatment
effect. Figure 5 illustrates this change by plotting the pie-
cewise constant hazard rate in each treatment arm for
the COOP trial. Extension to incorporate a random treat-
ment effect is also possible.
Discussion
The importance of having IPD available has been estab-
lished, allowing a full exploration of between-study hetero-
geneity [34] and the verification of model assumptions. By
obtaining IPD, computational issues may become apparent
with the sheer size of patient data being analysed when
incorporating random effects. This issue is clearly high-
lighted when using other large datasets within the hier-
archical Cox framework [14]. However, it should be noted
that a variety of techniques have been developed to
Table 8 One-stage IPD meta-analyses investigating the interaction between treatment and overweight status










Classical Treatment when wij = 0,
exp(βˆ1)
0.858 0.736 1.001 0.858 0.736 1.001 0.858 0.736 1.001 0.859 0.736 1.001
Overweight, exp(βˆ1) 0.726 0.630 0.835 0.725 0.630 0.835 0.726 0.630 0.835 0.726 0.630 0.835
Treatment when wij = 1,
exp(βˆ1 +γˆ )
0.896 0.784 1.024 0.896 0.784 1.023 0.896 0.784 1.024 0.896 0.784 1.024
Bayesian Treatment when wij = 0,
exp(βˆ1)
- - - 0.857 0.734 0.993 0.860 0.736 1.000 0.859 0.733 0.999
Overweight, exp(μˆ) - - - 0.725 0.634 0.836 0.726 0.632 0.838 0.725 0.631 0.840
Treatment when wij = 1,
exp(βˆ1 +γˆ )
- - - 0.896 0.781 1.022 0.896 0.787 1.023 0.897 0.785 1.025
Table 9 One-stage IPD meta-analyses investigating a non-proportional treatment effect
Framework Covariate Poisson (1) Poisson (0.5) Poisson (0.25)
Hazard Ratio 95% CI Hazard Ratio 95% CI Hazard Ratio 95% CI
Classical Treatment when t < 1, exp(βˆ1) 0.657 0.515 0.839 0.657 0.515 0.838 0.657 0.515 0.838
Treatment when t ≥ 1, exp(βˆ1 +φˆ) 0.935 0.837 1.045 0.936 0.838 1.045 0.936 0.838 1.045
Bayesian Treatment when t < 1, exp(βˆ1) 0.657 0.521 0.839 0.656 0.508 0.837 0.657 0.521 0.845
Treatment when t ≥ 1, exp(βˆ1 +φˆ) 0.934 0.833 1.049 0.936 0.841 1.045 0.935 0.835 1.042
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investigate heterogeneity and non-proportional hazards,
for example, when combining aggregate level data from
published studies [4,7-9,11].
In this paper, our aim was to illustrate an effective
alternative to hierarchical Cox models, minimising com-
putational issues and providing further interpretational
benefits. Through minimal splitting of follow-up time,
reliable estimates of effect can be obtained. Choice of
interval lengths will depend on the underlying shape of
the hazard function; however, the hazard ratio may be
insensitive to the baseline, as illustrated by consistent
estimates of the treatment effect across the 3 choices of
interval length used in this paper. By combining the Pois-
son approach with the collapsing technique described
above, we can dramatically reduce computation time.
When analysing data with rare events, such models may
be further advantageous through the need of less inter-
vals. Differential follow-up times between trials can also
be accounted for through this approach. Our approach
provides direct estimates of the baseline hazard rate
which is clinically important. These estimates allow the
calculation of risk differences, or number needed to treat
[40]. However, a limitation of our approach is that the
collapsing technique described cannot be used with truly
continuous covariates, such as age measured in days.
Investigation of random treatment effect models showed
a marked underestimation of heterogeneity under the
classical approach. This may in fact be explained by the
tendency of maximum likelihood to underestimate var-
iance parameters [28]. Under the Bayesian approach we
observed improved performance, with comparatively
lower absolute biases; however, it must be noted that,
given the nature of the MCMC algorithm, the Bayesian
approach will always provide a positive estimate of
between study heterogeneity. A recent simulation study
emphasised the need for care when choosing non-
informative priors on variance parameters [41], which has
specific relevance when investigating heterogeneity in the
treatment effect, as in Models C and D. An alternative
estimation procedure, such as h-likelihood [42], could be
investigated.
It must be noted that if purely interested in a pooled
treatment effect, then there is no advantage in pursuing
a one-stage over a two-stage approach; however, investi-
gation of treatment effect modifiers and modelling
assumptions should be conducted simultaneously, which
can only be done effectively through a one-stage
approach. Although previous work has provided effec-
tive methods to investigate heterogeneity in the meta-
analysis setting [14-17], we feel our approach provides a
highly simplistic alternative which can incorporate the
investigation of non-proportional hazards in covariate
effects, and that of treatment-effect modifiers, both of
which should be considered in any IPD meta-analysis.
In our analysis of the hypertension dataset, we
observed a 27.4% (95% CI: 16.55, 37.0%) reduction in
the mortality rate when a patient is overweight com-
pared to a non-overweight patient, with treatment group
held constant. Although this is a surprising result, it is
one that has been identified previously [43]. Previous
work by one of the authors of this article has also
observed this relationship between BMI and mortality;
however, further identified that the true factor lowering
risk is height, i.e. lower risk is seen for overweight
patients because they tend to be taller [44].
The approach detailed in this paper has the further
benefit of allowing adjustment for confounders to be
implemented simply. This becomes important when
analysing IPD from observational studies, where the
need to adjust for confounders is often paramount [45].
The flexibility of the Poisson approach described may
be extended through the use of splines to model not
only the baseline hazard, but also any time-dependent
effects [21]. This would result in more plausible predic-
tions, allowing a continuous function estimate of both.
Finally, we recognise that the IPD approach does not
necessarily solve all the problems for meta-analysis [46];
in particular, IPD may not be available from all the stu-
dies requested. In this situation a sensitivity analysis may
be needed to examine whether IPD meta-analysis conclu-
sions remain robust when aggregate data from non-IPD
studies are additionally included as far as possible [35].
Conclusion
For an IPD meta-analysis of survival data, our approach
provides a highly flexible and computationally efficient
framework. The methods are available in all standard
statistical software, allowing the investigation of not
only heterogeneity, but the presence of non-proportional


























Estimated hazard rate for the COOP trial
Figure 5 Estimated hazard rate in the COOP trial allowing for
non-proportional hazards in the treatment effect.
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Appendix
A.1. Model C: Random treatment effect with proportional
trial effects
Classical model within Stata:
. *load data
. use hyperdata, clear
. *stset the data
. stset fudy, failure(death = 1) id
(idnr) exit(time 5)
. *create time intervals by splitting at
every year
. stsplit sp, every(1)
. egen spgrp = group(sp)
. *generate offset
. qui gen y = _t-_t0
. *collapse across covariate patterns
. collapse (min) start = _t0 (max) end =
_t (count) n = _d (sum) y _d, by(spgrp
treat trial)
. *fit mixed effects Poisson model with
random treatment effect
. xtmepoisson _d i.treat i.trial ibn.
spgrp, exposure(y) nocons irr || trial:
treat, nocons
Bayesian model within WinBUGS:
model{
for (i in 1:N){
d[i] ~ dpois(mu[i]) #likelihood
log(mu[i]) < - alpha[trial[i]]*
(treat[i]-0.5) + beta[trial[i]] +
gamma[spgrp[i]] + log(y[i])
}
beta [1] < - 0
### Priors ###




tau < - 1/var
var < - pow(sd,2)
sd ~ dnorm(0,1)I(0,)
#Trial id:




for (q in 1:ints){
gamma[q] ~ dnorm(0.0,1.0E-6)
}
### Hazard ratio due to the treatment
effect:
expalpha < - exp(a)
}
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